Tamoxifen lowered breast cancer rates among high-risk women
Tamoxifen lowered breast cancer rates among high-risk women
PD-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer
CLL at ASH 2014: Expert discussion
BOLERO-1 reports HER2-positive breast cancer latest PFS data
Comment: Tamoxifen lowered breast cancer rates among high-risk women
Best of ASH 2014
ASH 2014: Highlights in CLL from ASH 2014
Oprozomib shows potential in the treatment of multiple myeloma
Ibrutinib as a single agent and in combination with dexamethasone showed anti-tumour activity in multiple myeloma
Hope for avoiding chemo in patients with Hodgkins lymphoma
Combination therapy for high-risk MDS? Not quite yet
ASH 2014: Highlights in mantle cell lymphoma